Search
13 hours ago
Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK
CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy...
14 hours ago
Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development
CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead...
1 day ago
With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space
Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as...
3 days ago
Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome
He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's...
3 days ago
The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy
Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations...
Feb 11
John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics
He gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and...
Jan 29
Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington's
Co-Founder and CEO David Reynolds describes why LoQus23 is taking a small molecule approach to neurodegenerative diseases and why they...
Jan 29
Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain
CEO Jan Thirkettle describes the company's approach to upregulating genes for neurodegenerative diseases and how Harness is out front in...
Jan 27
Akero's CEO comments on today's 96 week MASH data and the future of efruxifermin
Andrew Cheng describes the F4 patient population, and dicusses the efficacy and safety data Akero saw today. Plus, ongoing trials and how...
Jan 22
IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C
President and CEO Professor Mallory Factor KCNG describes the mechanism of the therapy and the company's commercial launch and hiring....
Jan 16
SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more
He highlights the company's current clinical programs, and talks about how thy are leveraging for the future the unique expertise in...
Jan 16
SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now
She describes how Siren is being built with a universal AAV platform, and is nearing its first IND in oncology. Plus, the fundraising...
Jan 16
SF Healthcare Week: The Co-Founder and CEO of Kardigan talks about this week's $300M series A financing to do precision medicine for cardiovascular disease
Tassos Gianakakos describes the round and the investors who participated in it, and hints at the personalized, biomarker driven approach...
Jan 15
SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development
He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous...
Jan 15
SF Healthcare Week: The CEO of Ionis talks about over 30 years of developing RNA therapies, and a new chapter as a commercial forward company
Brett Monia discusses the approval of TRYNGOLZA and an important data readout this year in severe hypertriglyceridemia. Plus, the...
Jan 15
SF Healthcare Week: Biohaven CEO Vlad Coric talks degraders, ion channel programs, and ADCs
He describes updates given for the degrader programs targeting IgG, IgA nephropathy, and peripartum cardiomyopathy.. Plus, ion channel...
Jan 15
SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, multiple myeloma, and lupus
She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the...
Jan 15
SF Healthcare Week: The CEO of Arvinas talks protein degradation, including about the industry's first phase 3 readout that is upcoming this quarter
John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination...
Jan 14
SF Healthcare Week: After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline
CEO John Jacobs describes the Sanofi deal, and combining Covid vaccines with flu vaccines. Plus, how the company is thinking about...
Jan 14
SF Healthcare Week: The CEO of Akeso talks about its PD1xVEGF, other bi-specific targets, and her opinion of China's position in the global biotech ecosystem
Chairman & CEO Michelle Xia describes the clinical trial that was run comparing the company's PD1xVEGF vs Akeso, development plans...
.png){kind=logo}
